Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer

Savient Pharmaceuticals

today announced the appointment of Kenneth J. Zuerblis as Executive Vice President & Chief Financial Officer, effective today. Mr. Zuerblis brings over 30 years of financial and operational experience to Savient and will be responsible for all financial, accounting and investor relations functions of the company. Mr. Zuerblis will report directly to John H. Johnson, Chief Executive Officer and President of Savient. "Ken brings to Savient a valuable combination of strategic, financial, operational and public company experience," said Mr. Johnson. "He has an impressive track record of growing organizations into profitable biopharmaceutical companies. I am confident that Ken's extensive experience will make him a tremendous asset to the company as we work toward achieving our goal of bringing KRYSTEXXA, the first and only FDA approved therapy for the treatment of refractory chronic gout, to the patients who need it around the world." Most recently, Mr. Zuerblis served as Chief Financial Officer and Senior Vice President of ImClone Systems, which develops targeted biologic cancer treatments, where he was responsible for leadership of all financial and investor relations operations until it was acquired by Eli Lilly and Company in November 2008.